Navigation Links
Medivation Announces Participation in Upcoming Conferences
Date:9/9/2009

SAN FRANCISCO, Sept. 9 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:

  • The BioCentury NewsMakers in the Biotech Industry Conference on Wednesday, September 16, at 11:30 a.m. Eastern Time at the Millennium Broadway Hotel in New York
  • The UBS Global Life Sciences Conference on Wednesday, September 23, at 9:00 a.m. Eastern Time at the Grand Hyatt in New York

Dr. Hung will provide an overview of Medivation and its clinical development programs including dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer.

A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
2. Medivation Announces Pricing of Public Offering
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
5. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
6. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Presents New Data on Dimebons Novel Mechanism of Action
8. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
9. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
11. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... PLAINVIEW, N.Y. , Jan. 18, 2017 ... pathology services, announces the formation of an Executive Committee ... 2017 and beyond. John Cucci , ... been promoted from Director of Business Development to ... in 2015, Mr. Cucci served in senior sales leadership ...
(Date:1/18/2017)... , Jan. 18, 2017 Applied ... mechanistic modeling to drug research and development, today ... Co-Founder, President, and CEO of Applied BioMath, will ... Informatics and Modeling (BAGIM) Meeting on Thursday January ... Cambridge , MA.   Dr. Burke,s talk ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... federally funded bio-focused Manufacturing Innovation Institutes (MII). U.S. Secretary of Commerce Penny Pritzker ... Biopharmaceuticals (NIIMBL), and the Department of Defense has announced the award of a ...
(Date:1/18/2017)... ... 18, 2017 , ... uBiome, the leading microbial genomics company, ... Editor, Dr. Elisabeth Bik, in the December 2016 issue of the Dutch Journal ... October 2016 from her previous position at Stanford University School of Medicine and ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
(Date:12/8/2016)...  Singulex, Inc., the leader in Next Generation Immunodiagnostics ... license and supply agreement with Thermo Fisher Scientific, the ... access to Thermo Scientific BRAHMS PCT (Procalcitonin), a biomarker ... to diagnose systemic bacterial infection and sepsis and in ... in assessing the risk of critically ill patients for ...
Breaking Biology News(10 mins):